Targovax announces collaboration to evaluate ONCOS-102 in combination with KEYTRUDA[®] in mesothelioma
· Targovax to collaborate in a randomized phase II trial investigating the combination ONCOS-102, Keytruda and standard of care chemotherapy in first line malignant pleural mesothelioma Oslo, Norway, 23 June 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that it has entered into a collaborative agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada) with the intent to initiate a randomized phase II trial to evaluate the combination of ONCOS-